Previous 10 | Next 10 |
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
Blueprint Medicines press release (NASDAQ:BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25. Revenue of $107M (+213.7% Y/Y) beats by $2.86M. Blueprint Medicines today announced it anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AY...
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results -- Achieved $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues in 2021 -- -- Anticipate approximately $115 million to $130 million in AYVAKIT net product revenues and $180 m...
Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is -$1.57 and the consensus revenue estimate is $104.14M (+205.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of the time...
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022 PR Newswire CAMBRIDGE, Mass. , Feb. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a l...
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis -- Positive opinion based on results from two clinical trials that comprise the largest clinical trial dataset in advanced systemic mas...
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team -- Philina Lee, Ph.D., promoted to Chief Commercial Officer -- -- Helen Ho, Ph.D., role expanded to Chief Business Officer - -- Demonstrates strong bench of talent and commitment to diversity in role...
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership -- Achieved full-year 2021 preliminary global net product revenue for AYVAKIT of approximately $52.9 million, representing an increase of approximately 150% over 2020 based on stron...
Blueprint Medicines Announces CEO and Leadership Transition Plan -- Jeff Albers to transition to role of Executive Chairman of the Board of Directors -- -- Chief Operating Officer Kate Haviland appointed President and Chief Executive Officer -- -- Chief Commercial Office...
Blueprint Medicines Completes Acquisition of Lengo Therapeutics - Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations - Investigational New Drug application for LNG-45...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire -- Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in adv...
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting PR Newswire -- Updated Phase 1 dose escalation data show that BLU...
WILMINGTON, Del., May 20, 2024 (GLOBE NEWSWIRE) -- The law firm of Andrews & Springer LLC, a boutique securities class action law firm focu...